Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Basal Plus vs Sliding Scale Insulin in Nursing Home Residents
NCT01131052Phase 4
Key facts
- Status
- Completed
- Start
- Mar 2011
- Primary completion
- Dec 2013
- Countries
- 1
- Modality
- Recombinant Proteins and Enzymes
- Drugs
- insulin glargine
- Conditions
- type 2 diabetes mellitus (T2DM)
01
Overview
Phase 4, randomised, open-label trial of insulin glargine in type 2 diabetes mellitus (T2DM) (2 arms). Primary endpoints: Percent of Participants With a Mean Blood Glucose Concentration of Less Than 70 mg/dL at 3 months, Percent of Participants With a Mean Blood Glucose Concentration of Less Than 40 mg/dL at 3 months and 1 more. Started Mar 2011; status: completed.
02
Design
2 arms- Study design
- RandomizedOpen-label
BASAL PLUS
Insulin Glargine once daily + Insulin Glulisine before meals/bedtime as needed
SSRI
Sliding Scale Regular Insulin before meals/bedtime as needed
03
Endpoints
Primary
Percent of Participants With a Mean Blood Glucose Concentration of Less Than 70 mg/dL
Percent of Participants With a Mean Blood Glucose Concentration of Less Than 40 mg/dL
Mean of Weekly Fasting Blood Glucose Concentration
Secondary
Mean Blood Glucose Concentration
Mean of Glycosylated Hemoglobin (hbA1c)
Mean of Daily Blood Glucose Concentration
Beyond the preview
Go deeper on NCT01131052.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01131052.